In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme

HealthTech approach

HealthTech approach

Advice programme

Area of interest

Showing 351 to 360 of 387

TitleTypeExpected publication date
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]Technology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]Technology appraisal guidance
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]Highly specialised technology
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis [ID6351]Technology appraisal guidanceTBC
Tolebrutinib for treating primary progressive multiple sclerosis [ID6574]Technology appraisal guidance
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]Technology appraisal guidanceTBC
Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713Technology appraisal guidanceTBC
Topical tapinarof for treating mild to severe plaque psoriasis ID6712Technology appraisal guidanceTBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]Technology appraisal guidance
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All